These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19017594)

  • 21. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
    Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
    Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB
    Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis.
    Jin CF; Sable R
    J Clin Gastroenterol; 2002 Jul; 35(1):100-1. PubMed ID: 12080238
    [No Abstract]   [Full Text] [Related]  

  • 30. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
    Leung CC; Law WS; Chang KC; Tam CM; Yew WW; Chan CK; Wong MY
    Chest; 2003 Dec; 124(6):2112-8. PubMed ID: 14665488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
    Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
    Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
    Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X
    Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
    Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
    [No Abstract]   [Full Text] [Related]  

  • 36. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
    White MC; Tulsky JP; Lee JR; Chen L; Goldenson J; Spetz J; Kawamura LM
    J Correct Health Care; 2012 Apr; 18(2):131-42. PubMed ID: 22419641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Toxic hepatitis caused by rifampin and isoniazid in treatment of tuberculosis (author's transl)].
    Abeledo Mezquita G; Otero Reigada MC
    An Esp Pediatr; 1977 Feb; 10(2):167-70. PubMed ID: 869341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of latent tuberculosis infection: a network meta-analysis.
    Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
    Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 40. Diseases of the respiratory system: tuberculosis.
    Seaton A
    Br Med J; 1978 Mar; 1(6114):701-3. PubMed ID: 630304
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.